Green M D, MacKay I R, Buckley J C, Coates A S
Aust N Z J Surg. 1979 Jun;49(3):335-9. doi: 10.1111/j.1445-2197.1979.tb07675.x.
The effects of treatment by immunotherapy and chemoimmunotherapy were assessed in 31 non-randomized patients with melanoma; 16 received only BCG and 15 BCG and chemotherapy. For advanced cases, the times of survival for the two treatment groups did not differ significantly, nor did there appear to be any improvement in survival over that recorded for the natural course of the disease. The pretreatment immune status as judged by hyporeactivity or normal reactivity to skin tests for delayed type hypersensitivity did not appear to influence survival. This study, together with other reports, does not support the use of immunotherapy in advanced melanoma. Immunotherapy for early melanoma is still to be assessed.
在31例非随机分组的黑色素瘤患者中评估了免疫疗法和化学免疫疗法的治疗效果；16例仅接受卡介苗治疗，15例接受卡介苗和化疗。对于晚期病例，两个治疗组的生存时间没有显著差异，与疾病自然病程记录的生存率相比，也没有出现任何改善。通过对迟发型超敏反应皮肤试验的低反应性或正常反应性判断的预处理免疫状态似乎不影响生存率。这项研究与其他报告一起，不支持在晚期黑色素瘤中使用免疫疗法。早期黑色素瘤的免疫疗法仍有待评估。
